Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics
XTalks
FEBRUARY 8, 2024
In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the US, impacted by prior formulary losses as well as “erosion of the basal insulin market,” the company said in the statement. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6
52 
Let's personalize your content